Effect of lornoxicam on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome

Cite item

Full Text


Aim. To evaluate the clinical efficacy, safety, and effects of the nonsteroidal anti-inflammatory drug lornoxicam on inflammatory markers in non-ST-segment elevation acute coronary syndrome (NSTEACS).
Subjects and methods. Eighty-five patients with NSTESCS were enrolled in a prospective randomized study. They were divided into 2 groups: 1) patients received lornoxicam (8 or 12 mg/daily) for 15 days in addition to standard treatment and 2) controls. Cardiovascular outcomes and the levels of C-reactive protein (CRP), IL-6, and IL-10 were determined.
Results. The lornoxicam group exhibited a significant reduction in CRP and a decrease in IL-6. There was also a significant increase in IL-10 levels in this group. A 6-month follow-up indicated a significant reduction in the number of cardiovascular events (nonfatal myocardial infarction, unstable angina, coronary death).
Conclusion. Lornoxicam reduces the risk of poor cardiovascular outcomes in patients with NSTEACS and the levels of inflammatory markers.

About the authors

Nikita Valer'evich Lomakin

Email: nikitalomakin@rambler.ru

Aleksey Kirillovich Gruzdev

Email: gruzdev@cch.pmc.ru

N V Lomakin

Central Clinical Hospital with Polyclinic, Department for Presidential Affairs of the Russian Federation

Central Clinical Hospital with Polyclinic, Department for Presidential Affairs of the Russian Federation

A K Gruzdev

Central Clinical Hospital with Polyclinic, Department for Presidential Affairs of the Russian Federation

Central Clinical Hospital with Polyclinic, Department for Presidential Affairs of the Russian Federation


  1. Богова О. Т., Чукаева И. И. Инфаркт миокарда. Воспаление и прогноз. Рус. кардиол. журн. 2003; 4(42): 95-97.
  2. Тепляков А. Т., Дибиров М. М., Болотская Л. А. и др. Модулирующее влияние карведилола на активацию цитокинов и регресс сердечной недостаточности у больных с постинфарктной дисфункцией сердца. Кардиология 2004; 9: 50-57.
  3. Ольбинская Л. И. Роль цитокиновой агрессии в патогенезе синдрома сердечной кахексии у больных с хронической сердечной недостаточностью. Обзор. сердеч. недостат. 2001; 2(3): 132-134.
  4. Ситникова М. Ю., Максимова Т. А., Вахрамеева Н. В. и др. Состояние эндотелия и маркеры хронического воспаления у больных ИБС, осложненной сердечной недостаточностью. Сердеч. недостат. 2002; 2: 80-82.
  5. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein albumin, or leucocyte count with coronary heart disease. J. A. M. A. 1998; 279: 1477-1482.
  6. Griselli M., Herbert J., Hutchinson W. L. et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J. Exp. Med. 1999; 190: 1733- 1740.
  7. Frangogiannis G., Mendoza L. H., Lindsey M. X. et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J. Immunol. 2000; 165(5): 2798-2808.
  8. Yamashita H., Shimada K., Seki E. et al. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am. J. Cardiol. 2003; 91(2): 133-136.
  9. Насонов Е. Л. Иммунологические маркеры атеросклероза. Тер. арх. 2002; 5: 80?85.
  10. Belton O., Fitzgerald D. J. Cyclooxygenase isoforms and atherosclerosis. Exp. Rev. Mol. Med. 2003; 5: 1-18.
  11. Cippollone F., Rocca B., Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 246-255.
  12. Cippolone F., Toniato E., Martinotti S. et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. J. A. M. A, 2004; 291: 2221-2228.
  13. Chenevard R., Hurlimann D., Bechir M. et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-409.
  14. Verma S., Rai S. R., Shewchuk L. et al. Cyclooxygenase-2 blocade does not impare endothelial vasodilatator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001; 104: 2879-2882.
  15. Title L. M., Giddens K., McInerney M. et al. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J. Am. Coll. Cardiol. 42: 1747-1753.
  16. Bogaty P., Brophy J. M., Noel M. et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein. A randomized placebo controlled study. Circulation 2004; 110: 934-939.
  17. Koo B., Kim Y., Park K. et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet 2007; 370(9587): 567-570.
  18. Bassand J. P., Hamm C. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2007; 28: 1598-1660.
  19. Werf F., Bax J. et al. Management of acute myocardial infarction in patients presenting with persistent ST segment elevation, ESC guidelines. Eur. Heart J. 2008; 29: 2909-2945.
  20. Altman R. et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: The nonsteroidal anti-inflammatory drugs in unstable angina treatment-2 (NUT-2) pilot study. Circulation 2002; 106: 191-195.
  21. Brochier M. L. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. Eur. Heart J. 1993; 14: 951-957.
  22. Bhara N., McClellan K. Indobufen: an updated review of its use in the management of atherothrombosis. Drugs Aging 2001; 18: 369-388.
  23. Kulik A., Ruel M. et al. Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial. Eur. J. Cardiothorac. Surg. 2004; 26(4):694-700.
  24. Применение нестероидных противовоспалительных препаратов: Клинические рекомендации / Лазебник Л. Б., Насонов Е. Л., Мареев В. Ю. и др. М., 2006.
  25. Lindahl B., Toss H., Siegbahn A. et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N. Engl. J. Med. 2000; 343: 1139-1147.
  26. Biasucci L., Liuzzo G., Grillo R. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-860.
  27. Monakier D. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 2004; 125(5): 1610-1615.
  28. Berg J. et al. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2 inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm. Res. 1999; 48: 369-379.

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies